The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease - A randomized, placebo-controlled, double-blind study

被引:86
作者
Alpsoy, E [1 ]
Er, H [1 ]
Durusoy, C [1 ]
Yilmaz, E [1 ]
机构
[1] Akdeniz Univ, Sch Med, Dept Dermatol, TR-07070 Antalya, Turkey
关键词
D O I
10.1001/archderm.135.5.529
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To determine the efficacy of topically applied sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease. Design and Setting: A randomized, placebo-controlled, double-blind study at a university referral center. Patients: Forty patients with Behcet disease were included in the study. Intervention: Patients were given topical sucralfate or placebo 4 times a day for 3 months and examined clinically at biweekly intervals. Main Outcomes Measures: For each lesion, the mean frequency, healing time, and pain were evaluated during the pretreatment, treatment, and follow-up periods. No patients were given any concurrent disease-specific or immunosuppressive topical and systemic drugs during the 9-month study period. Results: Of the 40 patients included in the study, the results in 30 patients (16 patients treated with sucralfate and 14 patients treated with placebo, ranging in age from 16 to 52 years [mean +/- SD age, 34.3 +/- 8.1 years]) were evaluable for efficacy. Treatment with sucralfate decreased significantly the mean frequency, healing time, and pain of oral ulceration and healing time and pain of genital ulceration compared with the pretreatment period. The effectiveness of sucralfate on the frequency and healing time of oral ulceration continued during the posttreatment period. In the placebo group, no significant difference was found in measured parameters of oral and genital ulceration except the pain of the oral ulceration between the pretreatment and treatment periods. Conclusion: Our results showed that topical sucralfate suspension is an easy, safe, inexpensive, and effective treatment for oral and genital ulceration in patients with Behcet disease.
引用
收藏
页码:529 / 532
页数:4
相关论文
共 21 条
[1]   INTERFERON THERAPY FOR BEHCETS-DISEASE [J].
ALPSOY, E ;
YILMAZ, E ;
BASARAN, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (04) :617-619
[2]  
Alpsoy Erkan, 1998, Journal of Dermatology (Tokyo), V25, P158
[3]   THE EFFECTS OF SUCRALFATE SUSPENSION AND DIPHENHYDRAMINE SYRUP PLUS KAOLIN-PECTIN ON RADIOTHERAPY-INDUCED MUCOSITIS [J].
BARKER, G ;
LOFTUS, L ;
CUDDY, P ;
BARKER, B .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1991, 71 (03) :288-293
[4]  
Behçet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
[5]   SUCRALFATE INDUCES PROLIFERATION OF DERMAL FIBROBLASTS AND KERATINOCYTES IN CULTURE AND GRANULATION-TISSUE FORMATION IN FULL-THICKNESS SKIN WOUNDS [J].
BURCH, RM ;
MCMILLAN, BA .
AGENTS AND ACTIONS, 1991, 34 (1-2) :229-231
[6]   SUCRALFATE SUSPENSION FOR STOMATITIS [J].
FERRARO, JM .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (02) :153-153
[7]  
GARNETT W R, 1982, Clinical Pharmacy, V1, P307
[8]  
JORIZZO JL, 1993, DERMATOLOGY GEN MED, P2290
[9]   ROLE OF NITRIC-OXIDE AND PROSTAGLANDINS IN SUCRALFATE-INDUCED GASTROPROTECTION [J].
KONTUREK, SJ ;
BRZOZOWSKI, T ;
MAJKA, J ;
CZARNOBILSKI, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (02) :277-279
[10]  
LAUDANNO OM, 1990, ITAL J GASTROENTEROL, V22, P19